Sardinian Village Emerges as Longevity Hotspot
Bolotana’s women show exceptional survival after 70, but researchers say longer observation is essential
A small mountain community in central Sardinia has emerged as a possible new longevity hotspot. Women in Bolotana recorded unusually favourable survival after the age of 70 between 2021 and 2025, according to a new demographic study. The finding is striking, but researchers caution that it does not yet establish the village as a permanent “blue zone” or reveal why residents live so long.
Exceptional survival among women
The peer-reviewed study published in Frontiers in Aging examined mortality among older residents of Bolotana, a municipality of approximately 2,266 people in Sardinia’s Marghine area.
Using mortality conditions recorded between 2021 and 2025, researchers estimated that a 70-year-old woman in Bolotana had a 13.83% likelihood of reaching 100. The corresponding estimates were 4.33% for Nuoro province, 4.43% for Sardinia and 3.54% for Italy as a whole.
Remaining life expectancy at 70 was estimated at 20.85 years for women in Bolotana, compared with 18.06 years nationally. Among the international populations included by the researchers, Bolotana’s female estimates ranked behind only Hong Kong.
The pattern was less pronounced among men. Male life expectancy at 70 was estimated at 16.02 additional years, while conditional survival from 70 to 100 was 4.92%. The uncertainty surrounding the male estimate was wide because it was derived from a small number of people and deaths.
These figures are period life-table estimates. They describe what would happen if the mortality conditions observed during the study remained constant. They are not predictions that any particular 70-year-old resident will live to 100.
Records were checked across generations
Claims of exceptional longevity require careful age verification. Errors in birth records, duplicated identities and unrecorded migration can distort statistics, especially when researchers are studying very small populations.
The Bolotana team cross-checked municipal records against independent parish registers. Names, birth and death dates, parents, family relationships and burial records were compared. Genealogical timelines were reconstructed when necessary to distinguish between siblings or residents with the same name.
During the principal observation period, the study recorded 3,138 person-years among residents aged 70 or older and 149 deaths in that age group. Nineteen residents reached 100, including 14 women and five men.
A separate historical analysis found that 38 of the 3,060 people born in Bolotana between 1900 and 1925 were documented as reaching 100. Local reporting from Sardinia has highlighted the quality of the village’s surviving civil and church archives as an important foundation for the research.
A candidate, not an established blue zone
The authors describe Bolotana as a candidate longevity blue zone. That qualification matters.
The observation period covered only five years and included the COVID-19 pandemic. In a small community, a relatively limited number of deaths can produce substantial changes in calculated survival. The confidence interval around the female estimate of reaching 100 ranged from 7.33% to 23.75%, illustrating the remaining statistical uncertainty.
The results also changed when the researchers examined an earlier period. In the 2015–2019 analysis, survival in Bolotana was lower than in Sardinia’s previously recognised longevity zone for both women and men. The study therefore concludes that longer observation is required before the village can be classified as an established longevity hotspot.
The comparisons with Italy, Sardinia and other populations were descriptive. They were not designed to establish formal statistical differences between communities of very different sizes.
The study does not identify a longevity formula
The research measures survival. It does not determine what caused it.
Bolotana’s geography, family structures, diet, physical activity, genetics, social connections and access to healthcare may all warrant investigation. The present demographic data, however, cannot distinguish between those explanations.
That distinction is important because the idea of blue zones has increasingly been used to promote diets, wellness programmes and commercial products. The study received no declared external funding, but one author owns Blue Zones, Inc. Another reported consulting compensation connected to a proposed Blue Zone Research Institute. Those interests were disclosed by the journal and should be considered when interpreting any commercial claims built around the findings.
Nothing in the study supports the conclusion that copying one food, routine or local custom will reproduce Bolotana’s survival pattern elsewhere. Individual-level health and lifestyle research would be required before causal conclusions could be drawn.
Ageing is more than a statistical achievement
Bolotana offers researchers a valuable opportunity to investigate why some communities may support longer lives. Yet longevity should not be reduced to the number of centenarians living within municipal boundaries.
Healthy ageing also depends on autonomy, secure housing, accessible healthcare, mobility and protection from isolation. As Europe confronts growing pressure on elderly care, the quality and dignity of additional years matter alongside their number.
The most responsible conclusion is therefore narrower than the headlines surrounding blue zones often suggest. Bolotana has produced a compelling, carefully validated demographic signal, particularly among women. Whether that advantage persists, and what may explain it, remain open scientific questions.
